Dong-A ST to Participate in 'CPHI 2023'... Expanding Global Business

Dong-A ST announced on the 7th that it participated in 'CPHI Worldwide 2023,' the world's largest pharmaceutical and bio exhibition, to expand its global business.

Booth views of Dong-A ST and ST Pharm set up at CPHI Worldwide 2023. [Photo by Dong-A ST]

CPHI is an exhibition held annually in major European countries, attended by companies across all sectors of pharmaceuticals and bio, including finished pharmaceuticals, active pharmaceutical ingredients, contract manufacturing organizations (CMO), and contract research organizations (CRO). Last year, more than 40,000 visitors attended the exhibition, with over 2,500 companies from more than 170 countries participating. This year, the event was held in Barcelona, Spain, from the 24th to the 26th (local time) for three days.

Except for the online events held in 2020 and 2021, Dong-A ST has participated every year since 2011. Since 2013, it has participated with a joint booth with ST Pharm, promoting its own developed new drugs and improved drugs, including ▲ Dong-A ST's research and development (R&D) and production capabilities ▲ the diabetes treatment drug Suganon ▲ the erectile dysfunction treatment drug Zaidenna ▲ the growth hormone drug Grotropin.

At this CPHI, Dong-A ST held business meetings with pharmaceutical and bio professionals from about 150 companies in 53 countries, seeking collaboration opportunities such as technology export and import, joint research, licensing out, and local production. Park Jae-hong, Head of R&D at Dong-A ST, personally participated in the business meetings, and Jeong Jae-hoon, President of Dong-A Socio Holdings, Kim Kyung-jin, President of ST Pharm, and Choi Kyung-eun, President of STGen Bio, also joined to support the promotion.

On the 24th, Dong-A ST attended the 'Accord Exclusive Partners Event' hosted by Accord Healthcare, which is responsible for the global sales of the Stelara biosimilar 'DMB-3115,' to pursue partnerships for sales in global markets including the U.S. and Europe. In July 2021, Dong-A ST signed a global license-out contract for DMB-3115 with multinational pharmaceutical company Intas. Intas plans to commercialize DMB-3115 worldwide through its subsidiaries, including Accord Biopharma in the U.S. and Accord Healthcare in Europe, the UK, and Canada. In June, the marketing authorization application was submitted to the European Medicines Agency, with the application completed in July, and preparations are underway for the U.S. marketing authorization application in the second half of this year.

Additionally, on the 24th, Dong-A ST signed a letter of intent (LOI) for cooperation on the diabetes treatment drug Suganon with Turkey's Berko Pharma and Orphamed Pharma, with plans to sign licensing and export contracts this year. On the 25th, licensing and export contracts for Suganon and Zaidenna were signed with Jordan's Nairoukh Pharma and its affiliate Misk Pharmaceutical.

Park Jae-hong, Head of R&D at Dong-A ST, said, "Many global pharmaceutical and bio professionals visited the Dong-A ST booth, paying attention to and showing interest in Dong-A ST's R&D and production capabilities. We were able to strengthen partnerships for the global market entry and sales of the Stelara biosimilar and achieve export contract results for our self-developed new drugs. We will continue our efforts not only at this CPHI but also in the global market to promote Dong-A ST's competitiveness and do our best to leap forward as a global healthcare company."

At the Accord Exclusive Partners Event, Alex Palgus, Senior Vice President of Accord Healthcare (first from the right), Paul Treadwell, CEO of Accord Healthcare (second from the right), Choi Kyung-eun, President of STGen Bio (third from the right), Chris Kokino, CEO of Accord Biopharma (fourth from the right), and Jae-hong Park, Head of R&D at Dong-A ST (fifth from the right) are taking a commemorative photo.
[Photo by Dong-A ST]

This content was produced with the assistance of AI translation services.